FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000735090> ?p ?o ?g. }

• W2000735090 endingPage "36992" @default.
• W2000735090 startingPage "36985" @default.
• W2000735090 abstract "Integrin-mediated adhesion is a crucial step in lymphocyte extravasation and homing. We show here that not only the chemokines CXCL12 and CXCL13 but also the lysophospholipids sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) enhance adhesion of murine follicular and marginal zone B cells to ICAM-1 in vitro. This process involves clustering of integrin LFA-1 and is blocked by pertussis toxin, suggesting that Gi family G-proteins are involved. In addition, lysophospholipid-induced adhesion on ICAM-1 depends on Rho and Rhokinase, indicative of an involvement of G12/G13, possibly also Gq/G11 family G-proteins. We used G12/G13- or Gq/G11-deficient B cells to study the role of these G-protein families in lysophospholipid-induced adhesion and found that the pro-adhesive effects of LPA and S1P are completely abrogated in G12/G13-deficient marginal zone B cells, reduced in G12/G13-deficient follicular B cells, and normal in Gq/G11-deficient B cells. We also show that loss of lysophospholipid-induced adhesion results in disinhibition of migration in response to the follicular chemokine CXCL13, which might contribute to the abnormal localization of splenic B cell populations observed in B cell-specific G12/G13-deficient mice in vivo. Taken together, this study shows that lysophospholipids regulate integrin-mediated adhesion of splenic B cells to ICAM-1 through Gi and G12/G13 family G-proteins but not through Gq/G11. Integrin-mediated adhesion is a crucial step in lymphocyte extravasation and homing. We show here that not only the chemokines CXCL12 and CXCL13 but also the lysophospholipids sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) enhance adhesion of murine follicular and marginal zone B cells to ICAM-1 in vitro. This process involves clustering of integrin LFA-1 and is blocked by pertussis toxin, suggesting that Gi family G-proteins are involved. In addition, lysophospholipid-induced adhesion on ICAM-1 depends on Rho and Rhokinase, indicative of an involvement of G12/G13, possibly also Gq/G11 family G-proteins. We used G12/G13- or Gq/G11-deficient B cells to study the role of these G-protein families in lysophospholipid-induced adhesion and found that the pro-adhesive effects of LPA and S1P are completely abrogated in G12/G13-deficient marginal zone B cells, reduced in G12/G13-deficient follicular B cells, and normal in Gq/G11-deficient B cells. We also show that loss of lysophospholipid-induced adhesion results in disinhibition of migration in response to the follicular chemokine CXCL13, which might contribute to the abnormal localization of splenic B cell populations observed in B cell-specific G12/G13-deficient mice in vivo. Taken together, this study shows that lysophospholipids regulate integrin-mediated adhesion of splenic B cells to ICAM-1 through Gi and G12/G13 family G-proteins but not through Gq/G11. Integrins are adhesion receptors that connect cells to extracellular matrix or to counter-receptors on other cells. Integrin-mediated adhesion is critically involved in a variety of processes such as tissue morphogenesis, wound healing, blood clotting, and leukocyte trafficking. In leukocytes, chemokines and their G-protein coupled receptors (GPCRs) 2The abbreviations used are: GPCR, G-protein coupled receptor; MZ B, marginal zone B; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; PTX, pertussis toxin; S1P, sphingosine 1-phosphate; LPA, lysophosphatidic acid; FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; TRITC, tetramethylrhodamine isothiocyanate; BSA, bovine serum albumin; FCS, fetal calf serum; ERK, extracellular signal-regulated kinase; PMA, phorbol 12-myristate 13-acetate. 2The abbreviations used are: GPCR, G-protein coupled receptor; MZ B, marginal zone B; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; PTX, pertussis toxin; S1P, sphingosine 1-phosphate; LPA, lysophosphatidic acid; FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; TRITC, tetramethylrhodamine isothiocyanate; BSA, bovine serum albumin; FCS, fetal calf serum; ERK, extracellular signal-regulated kinase; PMA, phorbol 12-myristate 13-acetate. play an important role in the regulation of integrin activity. While a wealth of studies addressed the role of chemokine receptors in lymphocyte homing to lymph nodes and Peyer′s patches (1Stein J.V. Nombela-Arrieta C. Immunology. 2005; 116: 1-12Crossref PubMed Scopus (185) Google Scholar, 2Butcher E.C. Williams M. Youngman K. Rott L. Briskin M. Adv. Immunol. 1999; 72: 209-253Crossref PubMed Google Scholar), not much is known about the regulation of B lymphocyte adhesion in the spleen. The spleen contains two subpopulations of mature B cells, follicular B cells and marginal zone B (MZ B) cells, the latter residing at the interface between red and white pulp, the marginal zone. Due to this localization at a site of early antigen contact and due to their high proliferative capacity, MZ B cells play an important role in the rapid defense against blood-borne bacterial antigens (3Martin F. Kearney J.F. Nat. Rev. Immunol. 2002; 2: 323-335Crossref PubMed Scopus (665) Google Scholar, 4Pillai S. Cariappa A. Moran S.T. Annu. Rev. Immunol. 2005; 23: 161-196Crossref PubMed Scopus (388) Google Scholar). Both entry of follicular B cells into the white pulp (5Lo C.G. Lu T.T. Cyster J.G. J. Exp. Med. 2003; 197: 353-361Crossref PubMed Scopus (140) Google Scholar) and MZ B cell localization within the marginal zone (6Lu T.T. Cyster J.G. Science. 2002; 297: 409-412Crossref PubMed Scopus (315) Google Scholar) depend on the interaction between lymphocyte integrins LFA (leukocyte function antigen)-1 and α4β1 and their respective ligands on stromal cells, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), respectively. A role for GPCRs in the regulation of this interaction was suggested based on pharmacological or genetic inactivation of different G-protein families in mice. For example, treatment with pertussis toxin (PTX), which ADP-ribosylates and thereby inactivates Gi family G-proteins, causes displacement of both follicular B cells and MZ B cells from their physiological niches (5Lo C.G. Lu T.T. Cyster J.G. J. Exp. Med. 2003; 197: 353-361Crossref PubMed Scopus (140) Google Scholar, 7Guinamard R. Okigaki M. Schlessinger J. Ravetch J.V. Nat. Immunol. 2000; 1: 31-36Crossref PubMed Scopus (433) Google Scholar), suggesting that Gi-coupled receptors normally contribute to splenic B cell homing. This hypothesis is strengthened by the finding that numbers of MZ B cells are low in mice lacking either the Gαi2 subunit of Gi (8Dalwadi H. Wei B. Schrage M. Spicher K. Su T.T. Birnbaumer L. Rawlings D.J. Braun J. J. Immunol. 2003; 170: 1707-1715Crossref PubMed Scopus (111) Google Scholar) or different effector molecules of the Gi family like Pyk-2, Rac2, or Dock2 (7Guinamard R. Okigaki M. Schlessinger J. Ravetch J.V. Nat. Immunol. 2000; 1: 31-36Crossref PubMed Scopus (433) Google Scholar, 9Croker B.A. Handman E. Hayball J.D. Baldwin T.M. Voigt V. Cluse L.A. Yang F.C. Williams D.A. Roberts A.W. Immunol. Cell Biol. 2002; 80: 231-240Crossref PubMed Scopus (53) Google Scholar, 10Fukui Y. Hashimoto O. Sanui T. Oono T. Koga H. Abe M. Inayoshi A. Noda M. Oike M. Shirai T. Sasazuki T. Nature. 2001; 412: 826-831Crossref PubMed Scopus (361) Google Scholar). In addition to Gi, also G12/G13 family G-proteins seem to be involved in splenic B cell localization, since MZ B cell numbers are reduced both in B cell-specific G12/G13-deficient mice (11Rieken S. Sassmann A. Herroeder S. Wallenwein B. Moers A. Offermanns S. Wettschureck N. J. Immunol. 2006; 177: 2985-2993Crossref PubMed Scopus (32) Google Scholar) and in mice lacking the G12/G13 effector Lsc/p115RhoGEF (12Girkontaite I. Missy K. Sakk V. Harenberg A. Tedford K. Potzel T. Pfeffer K. Fischer K.D. Nat. Immunol. 2001; 2: 855-862Crossref PubMed Scopus (145) Google Scholar). However, whether abnormal B cell localization in these mice is due to loss of GPCR-mediated integrin activation or secondary to other defects is not clear. To elucidate the mechanisms regulating B cell adhesion we studied the effects of chemokine and lysophospholipid GPCR agonists on integrin-mediated adhesion in splenic B cell populations. We show here that not only chemokines, but also the lysophospholipids S1P and LPA, enhance B cell adhesion to ICAM-1, but not to VCAM-1, and that this process involves LFA-1 clustering. We also show that, in contrast to chemokines, lysophospholipids mediate their effects not only through Gi family G-proteins but also through the G12/13/Rho/Rho-kinase signaling pathway, while Gq/11 family G-proteins are not involved. Animals—B cell-specific G12/G13-deficient mice and B cell-specific Gq/G11-deficient mice were generated by mating the B cell-specific CD19-Cre line (13Rickert R.C. Roes J. Rajewsky K. Nucleic Acids Res. 1997; 25: 1317-1318Crossref PubMed Scopus (557) Google Scholar) to Gna13fl/fl;Gna12-/- mice (14Moers A. Nieswandt B. Massberg S. Wettschureck N. Gruner S. Konrad I. Schulte V. Aktas B. Gratacap M.P. Simon M.I. Gawaz M. Offermanns S. Nat. Med. 2003; 9: 1418-1422Crossref PubMed Scopus (208) Google Scholar) and Gnaqfl/fl;Gna11-/- mice (15Wettschureck N. Rutten H. Zywietz A. Gehring D. Wilkie T.M. Chen J. Chien K.R. Offermanns S. Nat. Med. 2001; 7: 1236-1240Crossref PubMed Scopus (311) Google Scholar), respectively. Control mice (CD19-Cre-/-;Gna13fl/fl;Gna12+/+ or CD19-Cre-/-; Gnaqfl/fl;Gna11+/+, respectively) and B cell-specific double-deficient (CD19-Cre+/-;Gna13fl/fl;Gna12-/- or CD19-Cre+/-; Gnaqfl/fl;Gna11-/-, respectively) mice were generated by intercrosses of triple heterozygous parents. B cell-specific Gαq/Gα11-deficient mice were kept on a C57BL6/N background (eighth generation backcross), B cell-specific Gα12/Gα13-deficient mice were kept on a mixed C57BL6/N x Sv129J background, with a predominant contribution of the C57BL6/N strain (fourth generation backcross). Animals were housed under specific pathogen-free conditions. Genotyping was performed as described previously (14Moers A. Nieswandt B. Massberg S. Wettschureck N. Gruner S. Konrad I. Schulte V. Aktas B. Gratacap M.P. Simon M.I. Gawaz M. Offermanns S. Nat. Med. 2003; 9: 1418-1422Crossref PubMed Scopus (208) Google Scholar, 15Wettschureck N. Rutten H. Zywietz A. Gehring D. Wilkie T.M. Chen J. Chien K.R. Offermanns S. Nat. Med. 2001; 7: 1236-1240Crossref PubMed Scopus (311) Google Scholar). Flow Cytometry—Lymphocytes from splenocyte suspension were enriched with Lympholyte-M (Cedarlane, Hornby, Ontario, Canada). B lymphocyte subsets were analyzed with a three-color FACSCalibur flow cytometer and CellQuestPro software (BD Biosciences) using the following antibodies: anti-CD21-FITC, anti-CD23-PE, anti-B220/CD45R-Biotin, anti CD11a-Biotin, anti-CD18-Biotin, rat IgG2aκ isotype control, and SA-PerCP (all from BD Biosciences). Integrin Staining—Untouched B cells were prepared from splenocytes using a B cell isolation kit (Miltenyi, Bergisch-Gladbach, Germany), adhered to ICAM-1-coated coverslips (coated as described for adhesion assays) for 3, 10, or 30 min in the presence or absence of 100 nm S1P or LPA at 37 °C/5% CO2. Cells were then fixed in ice-cold 4% paraformaldehyde, washed twice in PBS, and incubated with biotinylated anti-CD11a antibody (BD Biosciences, 1:200) for 1 h. After washing in PBS, cells were incubated in SA-TRITC 1:200 in PBS with 2% fetal calf serum (FCS) for 1 h, washed, mounted in Mowiol, and analyzed on a Leica DC300F microscope. To quantify the effect of S1P or LPA on LFA-1 clustering, the number of CD11a clusters per cell was counted at ×63 magnification by an investigator blinded to genotype and treatment. Adhesion Assays—Adhesion assays were performed in 48-well plastic dishes as described (6Lu T.T. Cyster J.G. Science. 2002; 297: 409-412Crossref PubMed Scopus (315) Google Scholar) with minor modifications. For ICAM-1, wells were coated with 50 μg/ml goat-anti-human-IgG-Fc antibody (Jackson ImmunoResearch, West Grove, PA) at 4 °C overnight, washed twice with PBS, incubated with 2.5 μg/ml mouse ICAM-1-Fc (R&D Systems, Minneapolis, MN) in PBS for 2-3 h, and finally blocked with 0.5% BSA/PBS (100 μl per well for each step). Uncoated wells were treated with 0.5% BSA/PBS only. For VCAM-1, wells were incubated for 1 h at 37 °C with 100 μl/well 3 μg/ml hVCAM-1 (R&D Systems) in carbonate buffer and blocked with 0.5% BSA/PBS for 30 min before use. In some cases CXCL12 or CXCL13 were co-immobilized together with ICAM-1 or VCAM-1 at a concentration of 0.5 μg/ml. Lymphocytes were enriched with Lympholyte-M from splenocyte suspensions and incubated for 30 min in RPMI 1640 medium (Invitrogen, Karlsruhe, Germany) with 10 mm HEPES and 10% heat-inactivated FCS (Invitrogen) at 37 °C and 5% CO2 to remove contaminating macrophages. Non-adherent cells were washed twice, counted, and resuspended at a density of 2 × 107 cells/ml in RPMI 1640, 10 mm HEPES, 0.5% FCS. In some cases, cells were pretreated for 1 h at 37°C and 5% CO2 with 200 ng/ml PTX (Calbiochem/EMD Biosciences), 10 μm Y27632 (kind gift from Yoshitomi Pharmaceutical Inc., Osaka, Japan), or 0.2 μm TAT-C3 (16Vial E. Sahai E. Marshall C.J. Cancer Cell. 2003; 4: 67-79Abstract Full Text Full Text PDF PubMed Scopus (334) Google Scholar) before the adhesion assay. In these cases, the toxins were also present during adhesion. Blocking antibodies directed against CD11a or CD18 or isotype control antibodies (all from BD Biosciences; 1:200) were added only during adhesion. For the adhesion assay itself, 50 μl of cell suspension (1 × 107 cells/ml) were added to each well of the coated plate and mixed with 50 μl of RPMI 1640, 10 mm HEPES, 0.5% FCS containing 2× concentrated GPCR agonists. The following agonists were used (100 nm each if not otherwise indicated): SDF-1α/CXCL12 (Chemicon, Temecula CA), S1P (Biomol, Plymouth Meeting, PA), 1 μm LPA (Biomol), CXCL13/BCA-1 (R&D Systems). After 30 min of adhesion at 37 °C/5% CO2, non-adherent cells were discarded and adherent cells detached in RPMI 1640, 5 mm EDTA for 20 min on ice. Cells were then stained for B cell subpopulations with CD45R/B220-Biotin/SA-PerCP, CD21-FITC, CD23-PE (all from BD Biosciences) and resuspended in 200 μl of PBS, and data were acquired for 1 min. The absolute number of follicular (CD45R/B220pos, CD21int, CD23hi) and marginal zone (CD45R/B220pos, CD21hi, CD23lo) B cells was calculated and expressed as proportion of input into adhesion assay. Migration Assays—Lympholyte-M-purified splenocytes were preincubated in RPMI 1640, 10 mm HEPES, 0.1% BSA for 30 min at 37 and 5% CO2 and then allowed to migrate through uncoated, ICAM-1-coated, or VCAM-1-coated (coating see above) transwell inserts (5 μm pore size; Corning, Acton, MA) at a density of 2 × 106 splenocytes/100 μl/well. The lower wells contained 600 μl of RPMI 1640, 10 mm HEPES, 0.1% BSA either without chemokine or with 100 nm CXCL13. If indicated, 100 nm LPA was added to the upper well. After 2 h of incubation at 37 and 5% CO2, transwell plates were kept on ice for 20 min and centrifuged at 180 × g for 3 min, inserts were discarded, and cells were stained for B cell subpopulations as described above. Cell numbers were expressed as proportion of input. All experiments were done in triplicates. Reverse Transcription-PCR—B220pos, CD21hi, and CD23lo marginal zone B cells were sorted with a FACSVantage, and mRNA was prepared with a RNeasy mini kit (Qiagen, Hilden, Germany). Reverse transcription was performed according to standard protocols. LPA receptor subtypes were amplified with the following primers: S1P1,5′-GTGTAGACCCAGAGTCCTGCG-3′ and 5′-AGTACATGGGCCGGTGGAACT-3′; S1P3, 5′-GGAGCCCCTAGACGGGAGT-3′ and 5′-AGCCAAGTTGCCGATGAAAAAGT-3′; S1P4,5′-CCTGGAACTCACTTTATAGACCAGG-3′ and 5′-CCAGCCTGCCGCTGTGATTGTA-3′; LPA1, 5′-GCAGCTGCCTCTACTTCCAC-3′ and 5′-ACGCGCCGGTTGCTCATTC-3′; LPA2, 5′-TGGCGCCCCAAAGATGTGG-3′ and 5′-TAGCAACCCCAGACCCAGTG-3′; LPA3, 5′-GCAACACAGACACAGCGGAC-3′ and 5′-CCCACACCAGCAGAATGAGC-3′; LPA4, 5′-AACTGCATTCCTTACCAACATC-3′ and 5′-GAAAACAAAGAGGCTGAAATACC-3′; LPA5, 5′-GCAACACAGACACAGCGGAC-3′ and 5′-CCCACACCAGCAGAATGAGC-3′. RhoA Activation Assay—Levels of GTP-bound RhoA were determined in wild-type and mutant splenic B cells before and 1, 3, and 10 min after stimulation with 1 μm LPA using a G-LISA RhoA activation kit (Cytoskeleton, Denver, CO). Extracellular Signal-regulated Kinase (ERK) and Akt Phosphorylation—To determine phosphorylation of ERK and Akt in response to 1 μm LPA splenic lymphocytes were incubated at 37 °C in the presence or absence of agonist, then fixed for 10 min in 3% paraformaldehyde and permeabilized in 0.1% Triton X-100/PBS for 15 min. To determine ERK phosphorylation in MZ B cells, cells were incubated for 30 min with a FITC-labeled anti-ERK1/2 (pT202/pY204) antibody (BD Biosciences), PerCP-labeled anti-CD45R/B220 antibody, and PE-labeled anti-CD23 antibody, and the mean FITC intensity was determined in CD45R/B220pos and CD23neg cells (MZ B cells and newly formed B cells). To determine Akt phosphorylation in MZ B cells, cells were incubated for 30 min with a PE-labeled anti-Akt (pT308) antibody (BD Biosciences), PerCP-labeled anti-CD45R/B220 antibody, and FITC-labeled anti-CD21 antibody, and the mean PE-intensity was determined in CD45R/B220pos and CD21hi cells (MZ B cells). Data are displayed as mean fluorescence intensity as determined by the BD CellQuestPro Software. Western Blotting—Splenic B cells from control and mutant mice were isolated by magnetic cell sorting (Miltenyi, Bergisch-Gladbach, Germany), and membrane bound proteins were extracted as described earlier (17Mumby S.M. Heukeroth R.O. Gordon J.I. Gilman A.G. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 728-732Crossref PubMed Scopus (210) Google Scholar). Extracts from 106 cells per lane were electrophoresed on 10% SDS-PAGE gels and blotted onto nitrocellulose membranes according to standard protocols. Membranes were incubated overnight at 4 °C with polyclonal antibodies directed against Gα13 (1:1000), Gα12 (1:500), Gαi3 (1:500), and Gαq/11 (1:500) (all from Santa Cruz Biotechnology, Santa Cruz, CA) or α-tubulin antibodies for loading control (Clone DM1a, 1:1000; Sigma). Blots were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:2000; Sigma) for 1 h. Chemiluminescence was developed using the ECLplus kit (Amersham Biosciences, Freiburg, Germany). Statistics—Data are displayed as mean ± S.E. Comparisons between two groups were performed with Student's t test. Multiple comparisons were performed with analysis of variance and Bonferroni's post hoc test. To test whether GPCR activation contributes to B cell adhesion in vitro, we incubated murine splenic lymphocytes on ICAM-1- or VCAM-1-coated dishes in the presence or absence of different GPCR agonists and determined the percentage of adherent follicular B or MZ B cells, respectively. We found that the chemokines CXCL12 and CXCL13, as well as the protein kinase C activator phorbol 12-myristate 13-acetate (PMA), strongly enhanced adhesion on ICAM-1-coated plastic in both cell types (Fig. 1, A and B). On VCAM-1-coated dishes, basal adhesion was generally lower, and although PMA induced a mild but significant increase in adhesion of both MZ B cells and follicular B cell (adherent FoB cells: basal, 4 ± 0.7%; PMA, 10.8 ± 2.8%; adherent MZ B cells: 4.1 ± 0.5%; PMA, 8.5 ± 1.5%; p < 0.05), CXCL12 and CXCL13 failed to induce significant increases in adhesion (data not shown). Interestingly, also the lysophospholipids S1P and LPA strongly enhanced adhesion to ICAM-1 in both cell types (Fig. 1, A and B), while adhesion to VCAM-1 was not affected (data not shown). While effects of CXCL12 and CXCL13 on B cell adhesion have been described before (18Okada T. Ngo V.N. Ekland E.H. Forster R. Lipp M. Littman D.R. Cyster J.G. J. Exp. Med. 2002; 196: 65-75Crossref PubMed Scopus (416) Google Scholar), no direct data exist with respect to lysophospholipid-induced ICAM-1 adhesion. To characterize the pro-adhesive effects of S1P and LPA in more detail, we first tested the involvement of LFA-1, the main interaction partner of ICAM-1 on lymphocytes (19Arnaout M.A. Blood. 1990; 75: 1037-1050Crossref PubMed Google Scholar). We pretreated cells with blocking antibodies directed against LFA-1 α-chain CD11a or its β-chain CD18 and found that both treatments completely abrogated S1P- or LPA-induced adhesion of MZ B (Fig. 2A) and follicular B (Fig. 2B) cells, while pretreatment with isotype control antibodies did not affect adhesion. Two types of integrin activation have been described, enhanced affinity and increased clustering (20Hogg N. Henderson R. Leitinger B. McDowall A. Porter J. Stanley P. Immunol. Rev. 2002; 186: 164-171Crossref PubMed Scopus (143) Google Scholar, 22Stewart M. Hogg N. J. Cell. Biochem. 1996; 61: 554-561Crossref PubMed Scopus (222) Google Scholar), and we found that treatment with 100 nm S1P or LPA significantly enhanced the number of LFA-1 clusters per control cell (Fig. 2C), while we failed to detect increased binding of soluble ICAM-1 (data not shown). Taken together, these results indicate that lysophospholipids stimulate B cell adhesion to ICAM-1 and that this process involves enhanced LFA-1 clustering. Since most LPA and S1P receptor subtypes can couple to Gi family G-proteins (23Siehler S. Manning D.R. Biochim. Biophys. Acta. 2002; 1582: 94-99Crossref PubMed Scopus (111) Google Scholar, 24Takuwa Y. Takuwa N. Sugimoto N. J. Biochem. (Tokyo). 2002; 131: 767-771Crossref PubMed Scopus (146) Google Scholar), we investigated the role of Gi in lysophospholipid-induced B cell adhesion. Pretreatment of cells with PTX strongly inhibited S1P- or LPA-induced adhesion (Figs. 3, A and B), suggesting that Gi family G-proteins are involved. A potential toxic effect of PTX-treatment on Gi-independent pathways in primary B cells can be ruled out, since LPA-induced RhoA activation was not impaired in PTX-treated cells (Fig. 7D).FIGURE 7Intracellular signaling cascades activated in response to LPA in control B cells (WT), Gα12/Gα13-deficient B cells (G12/G13-/-), and PTX-treated control cells (WT+PTX). A and B, flow cytomertric analysis of the phosphorylation state of ERK1/2 (Thr-202/Tyr-204) or Akt (Thr-308) in MZ B cells without agonist (solid gray) and 20 min after stimulation with LPA 1 μm (unshaded area). Cells were stimulated, fixed, permeabilized and stained with the following antibodies: for A, FITC-anti-ERK1/2, PerCP-anti-CD45R/B220, PE-anti-CD23 (gate on CD45R/B220pos;CD23neg MZ B and newly formed B cells); for B PE-anti-Akt, PerCP-anti-CD45R/B220, FITC-anti-CD21 (gate on CD45R/B220pos;CD21hi MZ B cells). C, statistical evaluation of data from A and B, data are displayed as mean fluorescence intensity as determined by the BD CellQuestPro Software. D, levels of active, GTP-bound RhoA in control (black), PTX-treated control (gray), or Gα12/Gα13-deficient (white) B cells at different time points after LPA stimulation. *, p < 0.05; **, p < 0.005 versus corresponding untreated sample.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Also the small GTPase RhoA has been implicated in GPCR-mediated integrin activation (25Giagulli C. Scarpini E. Ottoboni L. Narumiya S. Butcher E.C. Constantin G. Laudanna C. Immunity. 2004; 20: 25-35Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar), and we tested the effects of the cell permeable version of the RhoA inhibitor Clostridium botulinum exoenzyme C3 (TAT-C3) (16Vial E. Sahai E. Marshall C.J. Cancer Cell. 2003; 4: 67-79Abstract Full Text Full Text PDF PubMed Scopus (334) Google Scholar) or the Rho-kinase inhibitor Y27632 (26Narumiya S. Ishizaki T. Uehata M. Methods Enzymol. 2000; 325: 273-284Crossref PubMed Google Scholar). Like PTX these toxins abrogated the pro-adhesive effects of S1P and LPA both in MZ B cells and in follicular B cells (Fig. 3, A and B), suggesting that also the RhoA/Rho-kinase cascade critically contributes to agonist-induced adhesion to ICAM. However, RhoA and Rho-kinase are not typically associated with activation of Gi but are rather a main effector pathway of the G12/G13 family of heterotrimeric G-proteins (27Narumiya S. Ishizaki T. Watanabe N. FEBS Lett. 1997; 410: 68-72Crossref PubMed Scopus (326) Google Scholar). Since this G-protein family has also been shown to couple to LPA and S1P receptors subtypes (23Siehler S. Manning D.R. Biochim. Biophys. Acta. 2002; 1582: 94-99Crossref PubMed Scopus (111) Google Scholar, 24Takuwa Y. Takuwa N. Sugimoto N. J. Biochem. (Tokyo). 2002; 131: 767-771Crossref PubMed Scopus (146) Google Scholar), we tested lysophospholipid-induced adhesion in B cells from B cell-specific G12/G13-deficient mice. Most strikingly, the pro-adhesive effects of S1P and LPA were completely abrogated in Gα12/Gα13-deficient MZ B cells, and reduced in follicular B cells. In contrast, chemokine-induced adhesion was normal (Fig. 4, A and B). We performed dose response experiments for S1P and LPA and found that while control mice showed a bell-shaped dose-response curve with maximal effects at 100 nm, none of the tested S1P and LPA concentrations enhanced ICAM-1 adhesion in Gα12/Gα13-deficient B cells (Fig. 4, C-F). In line with this we found that S1P and LPA did not induce significant LFA-1 clustering in mutant cells (Fig. 4G). Also pretreatment with PTX caused an abrogation of LPA- and S1P-induced LFA-1 clustering (Fig. 4G). This shows that lysophospholipid receptors mediate their pro-adhesive effects on ICAM-1 not only through Gi family G-proteins but also through G12/G13 family G-proteins, and both G-protein families are required for LFA-1 clustering. To test whether genetic inactivation of G12/G13 leads to altered expression of Gi3 or Gq/G11, we performed Western blotting experiments with wild-type and Gα12/Gα13-deficient B cells. We did not find significant differences in the protein levels of these α-subunits between the two genotypes (Fig. 5A). To rule out that impaired agonist-induced adhesion is due to reduced integrin expression, we analyzed expression of CD11a and CD18 by flow cytometry. We did not find major differences in the distribution of fluorescence intensity between the two genotypes (Fig. 5B), suggesting that it is indeed integrin activation, and not integrin expression, that is impaired in Gα12/Gα13-deficient B cells. To exclude major differences in the expression levels of S1P and LPA receptors between control and mutant B cells we performed reverse transcriptase polymerase chain reactions for the different receptor subtypes (Fig. 5C). As described by others (28Cinamon G. Matloubian M. Lesneski M.J. Xu Y. Low C. Lu T. Proia R.L. Cyster J.G. Nat. Immunol. 2004; 5: 713-720Crossref PubMed Scopus (338) Google Scholar), MZ B cells and follicular B cells expressed the S1P receptor subtypes S1P1, S1P3, and S1P4, and expression was comparable between control and mutant B cells. In addition, we found that MZ B and follicular B cells expressed the LPA receptor subtypes LPA2, LPA3, and weakly also LPA1 (Fig. 5C). Of the recently described non-Edg family receptors LPA4 (29Noguchi K. Ishii S. Shimizu T. J. Biol. Chem. 2003; 278: 25600-25606Abstract Full Text Full Text PDF PubMed Scopus (477) Google Scholar) and LPA5 (30Lee C.W. Rivera R. Gardell S. Dubin A.E. Chun J. J. Biol. Chem. 2006; 281: 23589-23597Abstract Full Text Full Text PDF PubMed Scopus (375) Google Scholar) only LPA4 was expressed in MZB cells. Also with respect to LPA receptor subtypes we did not find significant differences in expression levels between the genotypes (Fig. 5C). In addition to the G12/G13 family of G-proteins, the Gq/G11 family has been suggested to activate RhoA and Rho-kinase (31Chikumi H. Vazquez-Prado J. Servitja J.M. Miyazaki H. Gutkind J.S. J. Biol. Chem. 2002; 277: 27130-27134Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar, 33Vogt S. Grosse R. Schultz G. Offermanns S. J. Biol. Chem. 2003; 278: 28743-28749Abstract Full Text Full Text PDF PubMed Scopus (167) Google Scholar). We therefore investigated whether lysophopsholipid-induced adhesion to ICAM-1 was impaired in B cells from B cell-specific Gαq/Gα11-deficient mice but did not find significant differences between the genotypes (Fig. 6, A and B). In these experiments both basal and agonist-induced adhesion to ICAM-1 was lower than in cells from B cell-specific Gα12/Gα13-deficient mice and their respective controls, which is most likely due to differences in the genetic background. We next investigated which downstream effectors are activated in response to LPA in control, G12/G13-deficient, or PTX-treated B cells. We found that LPA induced phosphorylation of ERK1/2 and the serine/threonine protein kinase Akt/PKBAkt (Akt) (Fig. 7, A-C) in wild-type cells. In addition, LPA induced activation of RhoA (Fig. 7D) in wild-type cells. Both ERK and Akt phosphorylation were completely abrogated in PTX-pretreated cells, while in G12/G13-deficient B cells Akt phosphorylation was normal and ERK phosphorylation only slightly reduced (Fig. 7, A-C). In contrast, PTX treatment did not affect the LPA-induced increase in active, GTP-bound RhoA, while LPA-induced RhoA activation was completely abrogated in G12/G13-deficient B cells (Fig. 7D). B cell-specific Gα12/Gα13-deficient mice show strongly reduced numbers of marginal zone B cells (11Rieken S. Sassmann A. Herroeder S. Wallenwein B. Moers A. Offermanns S. Wettschureck N. J. Immunol. 2006; 177: 2985-2993Crossref PubMed Scopus (32) Google Scholar), and we asked whether impaired agonist-induced adhesion to ICAM-1 might contribute to this phenotype. It has been suggested that integrin-mediated adhesion within the marginal zone contributes to MZ B cell homing by counteracting promigratory signals like CXCL13 from adjacent follicles (6Lu T.T. Cyster J.G. Science. 2002; 297: 409-412Crossref PubMed Scopus (315) Google Scholar). We therefore tested whether lysophospholipid-mediated enhancement of adhesion impairs migration toward CXCL13 in vitro. Since S1P exerts strong promigratory effects itself (28Cinamon G. Matloubian M. Lesneski M.J. Xu Y. Low C. Lu T. Proia R.L. Cyster J.G. Nat. Immunol. 2004; 5: 713-720Crossref PubMed Scopus (338) Google Scholar) and was also shown to facilitate chemokine-induced migration in splenic lymphocytes (34Yopp A.C. Ochando J.C. Mao M. Ledgerwood L. Ding Y. Bromberg J.S. J. Immunol. 2005; 175: 2913-2924Crossref PubMed Scopus (36) Google Scholar), we used LPA in these experiments. We found that addition of LPA to the upper transwell chamber indeed resulted in a significant reduction of both basal (Fig. 8A, left) and CXCL13-induced (Fig. 8B, left) migration through ICAM-1-coated inserts in control cells. Gα12/Gα13-deficient cells did not differ from control cells with respect to basal or CXCL13-induced migration; however, the anti-migratory effect of LPA was strongly reduced in mutant cells (Fig. 8, A and B, right). This indicates that the lysophospholipid-induced inhibition of CXCL13-dependent B cell chemotaxis depends on the G12/G13-mediated signaling pathway. Inhibition of migration was not present on uncoated transwell inserts (Fig. 8, C and D) or VCAM-1 coated inserts (data not shown), suggesting that ICAM-1-mediated adhesion is underlying this effect. Taken together, these results show that not only chemokines, but also lysophospholipids, can enhance B cell adhesion to ICAM-1 in vitro. The pro-adhesive effects of lysophospholipids are mediated both through Gi family G-proteins and the G12/G13/RhoA/Rho-kinase pathway, but do not involve Gq/G11 family G-proteins. Loss of lysophospholipid-induced adhesion causes disinhibition of migration in response to the follicular chemokine CXCL13, which might contribute to the abnormal localization of splenic B cell populations in B cell-specific G12/G13-deficient mice. The molecular mechanisms governing integrin-mediated adhesion of splenic B cells are not well understood. We show here that not only chemokines, but also lysophospholipids enhance adhesion of murine B cells to ICAM-1 in vitro, and that this process involves LFA-1 clustering. Integrin activation by non-chemokine GPCRs has been reported in a variety of cellular systems, e.g. for thrombin and thromboxane A2 receptors in platelets (35Stouffer G.A. Smyth S.S. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 1971-1978Crossref PubMed Scopus (41) Google Scholar, 37Brass L.F. Manning D.R. Cichowski K. Abrams C.S. Thromb. Haemostasis. 1997; 78: 581-589Crossref PubMed Scopus (165) Google Scholar), or for S1P in human and murine cell lines (38Yamamura S. Hakomori S. Wada A. Igarashi Y. Ann. N. Y. Acad. Sci. 2000; 905: 301-307Crossref PubMed Scopus (22) Google Scholar, 39Paik J.H. Chae S. Lee M.J. Thangada S. Hla T. J. Biol. Chem. 2001; 276: 11830-11837Abstract Full Text Full Text PDF PubMed Scopus (258) Google Scholar). Indirect evidence for a role of S1P in integrin-mediated processes comes from genetic or pharmacological inactivation of the S1P1 receptor, which causes impaired lymphocyte entry into secondary lymphoid organs (40Halin C. Scimone M.L. Bonasio R. Gauguet J.M. Mempel T.R. Quackenbush E. Proia R.L. von Mandala S. Andrian U.H. Blood. 2005; 106: 1314-1322Crossref PubMed Scopus (99) Google Scholar) and dislocation of MZ B cells from the marginal zone (28Cinamon G. Matloubian M. Lesneski M.J. Xu Y. Low C. Lu T. Proia R.L. Cyster J.G. Nat. Immunol. 2004; 5: 713-720Crossref PubMed Scopus (338) Google Scholar, 41Vora K.A. Nichols E. Porter G. Cui Y. Keohane C.A. Hajdu R. Hale J. Neway W. Zaller D. Mandala S. J. Leukocyte Biol. 2005; 78: 471-480Crossref PubMed Scopus (42) Google Scholar). We also show that lysophospholipid-induced adhesion depends on both Gi and G12/G13 family G-proteins, while chemokine-induced adhesion does not require G12/G13. This finding is in line with the general assumption that chemokine GPCRs signal primarily through Gi family G-proteins (42Baggiolini M. Dewald B. Moser B. Annu. Rev. Immunol. 1997; 15: 675-705Crossref PubMed Scopus (1968) Google Scholar), while lysophospholipid receptors can utilize a variety of different G-protein families (23Siehler S. Manning D.R. Biochim. Biophys. Acta. 2002; 1582: 94-99Crossref PubMed Scopus (111) Google Scholar). It is not completely clear why activation of Gi through chemokine receptors is sufficient to enhance adhesion to ICAM-1, while activation of lysophospholipid receptors requires both Gi and G12/G13 to do so. Possible explanations might be differences in the expression levels of chemokine versus lysophospholipid receptors or differences in the signaling efficiency of the respective receptors. MZ B cells and follicular B cells express the S1P receptor subtypes S1P1, S1P3, and S1P4 (28Cinamon G. Matloubian M. Lesneski M.J. Xu Y. Low C. Lu T. Proia R.L. Cyster J.G. Nat. Immunol. 2004; 5: 713-720Crossref PubMed Scopus (338) Google Scholar) and according to our results also LPA1, LPA2, and LPA3. While S1P1 and LPA3 are believed to activate predominantly Gi family G-proteins, LPA1, LPA2, S1P3, and S1P4 were shown to couple to both Gi and G12/G13 (24Takuwa Y. Takuwa N. Sugimoto N. J. Biochem. (Tokyo). 2002; 131: 767-771Crossref PubMed Scopus (146) Google Scholar, 43Anliker B. Chun J. J. Biol. Chem. 2004; 279: 20555-20558Abstract Full Text Full Text PDF PubMed Scopus (247) Google Scholar, 44Graler M.H. Goetzl E.J. Biochim. Biophys. Acta. 2002; 1582: 168-174Crossref PubMed Scopus (151) Google Scholar). Our results show that the pro-adhesive effects of lysophospholipids are mediated both through G12/G13 and Gi-type G-proteins. Such co-operativity between different G-protein families has been described in other systems, e.g. in platelets, where activation of Gi-mediated signaling alone is unable to trigger full activation of integrin αIIbβ3 but requires co-activation of Gi and G12/G13 family G-proteins (45Dorsam R.T. Kim S. Jin J. Kunapuli S.P. J. Biol. Chem. 2002; 277: 47588-47595Abstract Full Text Full Text PDF PubMed Scopus (111) Google Scholar, 47Nieswandt B. Schulte V. Zywietz A. Gratacap M.P. Offermanns S. J. Biol. Chem. 2002; 277: 39493-39498Abstract Full Text Full Text PDF PubMed Scopus (109) Google Scholar). In addition to the role of G-proteins, we were able to show that lysophospholipid-induced integrin activation involves the small GTPase RhoA and its effector Rho-kinase. This is consistent with a variety of studies showing an involvement of RhoA in integrin-mediated adhesion (25Giagulli C. Scarpini E. Ottoboni L. Narumiya S. Butcher E.C. Constantin G. Laudanna C. Immunity. 2004; 20: 25-35Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar, 48Vielkind S. Gallagher-Gambarelli M. Gomez M. Hinton H.J. Cantrell D.A. J. Immunol. 2005; 175: 350-357Crossref PubMed Scopus (57) Google Scholar, 50Tominaga T. Sugie K. Hirata M. Morii N. Fukata J. Uchida A. Imura H. Narumiya S. J. Cell Biol. 1993; 120: 1529-1537Crossref PubMed Scopus (206) Google Scholar). Although G12/G13 are believed to be the major mediators of RhoA activation in response to GPCR stimulation, it has been shown that also Gq/G11 family G-proteins can activate RhoA (31Chikumi H. Vazquez-Prado J. Servitja J.M. Miyazaki H. Gutkind J.S. J. Biol. Chem. 2002; 277: 27130-27134Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar, 32Booden M.A. Siderovski D.P. Der C.J. Mol. Cell. Biol. 2002; 22: 4053-4061Crossref PubMed Scopus (147) Google Scholar). We did not find differences with respect to lysophospholipid-induced adhesion between control and Gαq/Gα11-deficient B cells, while LPA-induced RhoA activation is completely abrogated in G12/G13-deficient B cells. Both findings strongly suggest that Gq/G11-mediated Rho activation is not critical in this setting, which is in line with the finding that ligand-induced RhoA activation through Gq/G11 occurs with lower potency than G12/G13-mediated Rho activation (33Vogt S. Grosse R. Schultz G. Offermanns S. J. Biol. Chem. 2003; 278: 28743-28749Abstract Full Text Full Text PDF PubMed Scopus (167) Google Scholar). We were able to show that LPA induces not only RhoA activation but also phosphorylation of ERK and Akt in MZ B cells and that the latter effect is predominantly mediated by Gi. Although our data do not prove that ERK- and Akt-phosphorylation are critically involved in the proadhesive effects of LPA, our findings suggest that in addition to the G12/13/RhoA/ROCK signaling cascade also Gi-mediated ERK and Akt phosphorylation are required for LPA-induced pro-adhesive effects in MZ B cells. B cell-specific Gα12/Gα13-deficient mice show strongly reduced numbers of splenic MZ B cells but not of follicular B cells (11Rieken S. Sassmann A. Herroeder S. Wallenwein B. Moers A. Offermanns S. Wettschureck N. J. Immunol. 2006; 177: 2985-2993Crossref PubMed Scopus (32) Google Scholar). This selective loss of MZ B cells has been attributed to a strong enhancement of migration in these cells (11Rieken S. Sassmann A. Herroeder S. Wallenwein B. Moers A. Offermanns S. Wettschureck N. J. Immunol. 2006; 177: 2985-2993Crossref PubMed Scopus (32) Google Scholar), but it seems likely that also impaired lysophospholipid-induced adhesion to ICAM-1 contributes to the phenotype. Lysophospholipids are highly abundant in the blood (51Hla T. Pharmacol. Res. 2003; 47: 401-407Crossref PubMed Scopus (237) Google Scholar, 52Spiegel S. Milstien S. Nat. Rev. Mol. Cell. Biol. 2003; 4: 397-407Crossref PubMed Scopus (1724) Google Scholar) and therefore seem well suited to mediate localization of lymphocytes to specialized anatomical sites with low blood flow and high ICAM-1 expression such as the marginal zone (6Lu T.T. Cyster J.G. Science. 2002; 297: 409-412Crossref PubMed Scopus (315) Google Scholar). Taken together, this study shows that lysophospholipids regulate LFA-1-dependent adhesion of B cells to ICAM-1 and that this effect depends both on Gi and the G12/13/Rho/Rho-kinase signaling pathway. Loss of GPCR-mediated pro-adhesive effects might contribute to low MZ B cell numbers observed in mouse models with genetic or pharmacological inactivation of Gi (5Lo C.G. Lu T.T. Cyster J.G. J. Exp. Med. 2003; 197: 353-361Crossref PubMed Scopus (140) Google Scholar, 7Guinamard R. Okigaki M. Schlessinger J. Ravetch J.V. Nat. Immunol. 2000; 1: 31-36Crossref PubMed Scopus (433) Google Scholar, 8Dalwadi H. Wei B. Schrage M. Spicher K. Su T.T. Birnbaumer L. Rawlings D.J. Braun J. J. Immunol. 2003; 170: 1707-1715Crossref PubMed Scopus (111) Google Scholar) or G12/G13 (11Rieken S. Sassmann A. Herroeder S. Wallenwein B. Moers A. Offermanns S. Wettschureck N. J. Immunol. 2006; 177: 2985-2993Crossref PubMed Scopus (32) Google Scholar). We thank K. Rajewsky for providing the CD19-Cre mouse line, M. Scheuermann for help with FACS sorting, and A. Rogatzki, M. Hillesheim, and Y. Teschner for expert technical assistance." @default.
• W2000735090 created "2016-06-24" @default.
• W2000735090 creator A5022130403 @default.
• W2000735090 creator A5037564002 @default.
• W2000735090 creator A5056429976 @default.
• W2000735090 creator A5070960615 @default.
• W2000735090 creator A5073536514 @default.
• W2000735090 creator A5080547151 @default.
• W2000735090 creator A5089894090 @default.
• W2000735090 date "2006-12-01" @default.
• W2000735090 modified "2023-09-28" @default.
• W2000735090 title "Lysophospholipids Control Integrin-dependent Adhesion in Splenic B Cells through Gi and G12/G13 Family G-proteins but Not through Gq/G11" @default.
• W2000735090 cites W1485975953 @default.
• W2000735090 cites W1525378600 @default.
• W2000735090 cites W1533702935 @default.
• W2000735090 cites W1535141082 @default.
• W2000735090 cites W1553815101 @default.
• W2000735090 cites W1561493617 @default.
• W2000735090 cites W1588069091 @default.
• W2000735090 cites W1935225932 @default.
• W2000735090 cites W1937674947 @default.
• W2000735090 cites W1967534082 @default.
• W2000735090 cites W1978893911 @default.
• W2000735090 cites W1988839950 @default.
• W2000735090 cites W1989550450 @default.
• W2000735090 cites W1992365461 @default.
• W2000735090 cites W1999927753 @default.
• W2000735090 cites W1999975964 @default.
• W2000735090 cites W2002293674 @default.
• W2000735090 cites W2003150686 @default.
• W2000735090 cites W2020114437 @default.
• W2000735090 cites W2022157262 @default.
• W2000735090 cites W2022770236 @default.
• W2000735090 cites W2043290332 @default.
• W2000735090 cites W2044163981 @default.
• W2000735090 cites W2045594979 @default.
• W2000735090 cites W2049160111 @default.
• W2000735090 cites W2049897598 @default.
• W2000735090 cites W2054613918 @default.
• W2000735090 cites W2055748995 @default.
• W2000735090 cites W2056683808 @default.
• W2000735090 cites W2063229662 @default.
• W2000735090 cites W2064489682 @default.
• W2000735090 cites W2076244069 @default.
• W2000735090 cites W2077235132 @default.
• W2000735090 cites W2082220789 @default.
• W2000735090 cites W2082849113 @default.
• W2000735090 cites W2085488090 @default.
• W2000735090 cites W2091629951 @default.
• W2000735090 cites W2095430146 @default.
• W2000735090 cites W2097480084 @default.
• W2000735090 cites W2119005151 @default.
• W2000735090 cites W2120249729 @default.
• W2000735090 cites W2126494959 @default.
• W2000735090 cites W212830756 @default.
• W2000735090 cites W2130963215 @default.
• W2000735090 cites W2132729419 @default.
• W2000735090 cites W2133249296 @default.
• W2000735090 cites W2156075377 @default.
• W2000735090 cites W2160272188 @default.
• W2000735090 cites W2166588660 @default.
• W2000735090 cites W2167808722 @default.
• W2000735090 cites W2168774705 @default.
• W2000735090 cites W4238785086 @default.
• W2000735090 doi "https://doi.org/10.1074/jbc.m605287200" @default.
• W2000735090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17023430" @default.
• W2000735090 hasPublicationYear "2006" @default.
• W2000735090 type Work @default.
• W2000735090 sameAs 2000735090 @default.
• W2000735090 citedByCount "34" @default.
• W2000735090 countsByYear W20007350902012 @default.
• W2000735090 countsByYear W20007350902013 @default.
• W2000735090 countsByYear W20007350902014 @default.
• W2000735090 countsByYear W20007350902015 @default.
• W2000735090 countsByYear W20007350902016 @default.
• W2000735090 countsByYear W20007350902019 @default.
• W2000735090 countsByYear W20007350902020 @default.
• W2000735090 countsByYear W20007350902023 @default.
• W2000735090 crossrefType "journal-article" @default.
• W2000735090 hasAuthorship W2000735090A5022130403 @default.
• W2000735090 hasAuthorship W2000735090A5037564002 @default.
• W2000735090 hasAuthorship W2000735090A5056429976 @default.
• W2000735090 hasAuthorship W2000735090A5070960615 @default.
• W2000735090 hasAuthorship W2000735090A5073536514 @default.
• W2000735090 hasAuthorship W2000735090A5080547151 @default.
• W2000735090 hasAuthorship W2000735090A5089894090 @default.
• W2000735090 hasBestOaLocation W20007350901 @default.
• W2000735090 hasConcept C153911025 @default.
• W2000735090 hasConcept C170493617 @default.
• W2000735090 hasConcept C178790620 @default.
• W2000735090 hasConcept C185592680 @default.
• W2000735090 hasConcept C195687474 @default.
• W2000735090 hasConcept C55493867 @default.
• W2000735090 hasConcept C84416704 @default.
• W2000735090 hasConcept C86803240 @default.
• W2000735090 hasConcept C95444343 @default.
• W2000735090 hasConceptScore W2000735090C153911025 @default.
• W2000735090 hasConceptScore W2000735090C170493617 @default.

• next